Forest Laboratories Namenda Alzheimer’s Drug Antitrust Complaint

February 28, 2020

This antitrust class action alleges that Forest Laboratories, LLC attempted to retain its monopoly on its $1.5 billion-per-year drug, Namenda IR by preventing less expensive generics from coming to market. Namenda IR is prescribed to treat moderate to severe dementia in Alzheimer’s patients. It was approved by the Food and Drug Administration (FDA) in 2003.

Case Event File: Forest Laboratories Namenda Alzheimer’s Drug Antitrust Complaint

Related to: Forest Laboratories Namenda Alzheimer’s Drug Antitrust Class Action